Table I.
Patient characteristics (n=44).
| Characteristics | SRS group (n=24) | WBRT group (n=20) | P-value |
|---|---|---|---|
| Median age, years (range) | 67.6 (46–80) | 67.5 (49–84) | 0.519 |
| Sex (male/female) | 17/7 | 10/10 | 0.158 |
| Histology (Ad/Sq/others) | 23/1/0 | 17/1/2 | 0.278 |
| Smoking status (current/former/never) | 7/11/6 | 4/8/8 | 0.542 |
| EGFR/ALK mutation status (positive/negative/unknown) | 13/9/2 | 11/4/5 | 0.219 |
| Clinical stage at diagnosis (I–II/III/IV) | 1/6/17 | 3/1/16 | 0.118 |
| ECOG-PS (0/1/2/3/4) | 7/12/1/3/1 | 3/9/3/3/2 | 0.554 |
| Prior TKI (yes/no) | 4/20 | 5/15 | 0.710 |
| Prior chemotherapy (yes/no) | 7/17 | 8/12 | 0.450 |
| Symptoms from BMs (yes/no) | 7/17 | 8/12 | 0.450 |
| Number of BMs, median (range) | 11 (10–19) | 15 (10–20) | 0.008 |
| Maximum diameter of BMs median, mm (range) | 17.0 (8–40) | 13.5 (5–32) | 0.069 |
| Extracranial metastases (present/absent) | 24/0 | 17/3 | 0.086 |
| DS-GPA score (0–1.0/1.5–2.0/2.5-) | 17/7/0 | 14/6/0 | 0.952 |
| Lung-molGPA score (0–1.0/1.5–2.0/2.5-) | 8/9/7 | 6/9/5 | 0.879 |
| Subsequent chemotherapy (yes/no) | 14/10 | 12/8 | 0.911 |
| Subsequent TKI (yes/no) | 11/13 | 10/10 | 0.783 |
| Salvage treatment (yes/no) | 10/14 | 1/19 | 0.005 |
SRS, stereotactic radiosurgery; WBRT, whole brain radiotherapy; Ad, adenocarcinoma; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; TKI, tyrosine kinase inhibitor; BMs, brain metastases; DS-GPA, diagnosis-specific graded prognostic assessment.